Clinical study on mometasone furoate nasal spray in the treatment of non-allergic rhinitis
10.3760/cma.j.issn.1673-0860.2010.12.004
- VernacularTitle:糠酸莫米松鼻喷剂治疗非变应性鼻炎的多中心临床研究
- Author:
Ke-Jun ZUO
1
;
A.Sail GIYAB
;
Geng XU
;
Zhen DONG
;
Luo ZHANG
;
Li SHI
;
De-Hui WANG
;
Jian-Yun XIAO
;
Qiu-Hang ZHANG
;
Xue-Yuan ZHANG
Author Information
1. 中山大学附属第一医院
- Keywords:
Rhinitis,vasomotor;
Glucocorticoids;
Endoscopy;
Multicenter study;
Rhinitis,non-allergic
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2010;45(12):982-987
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the outcome of mometasone furoate nasal spray (MFNS) used for 3 months on non-allergic rhinitis (NAR). Methods In this multicenter study, NAR patients were enrolled from eight hospitals and received MFNS 200 microgram once daily for 3 months. The patients were followed-up for three times (at baseline, month 1 and month 3) to record the symptom scores and nasal endoscopic appearances. At the same time, the adverse events frequency was recorded and analyzed.Results A total of 188 NAR cases were enrolled in the study. The total nasal symptom score assessment descended significantly at month 1 (1.70 ± 0. 75) and month 3 (0. 95 ± 0. 79) visits versus at baseline (2. 67 ± 0. 68, Z value were from - 11. 603 to - 10. 491, all P < 0. 01). The individual symptoms,including nasal stuffiness, nasal discharge, nasal stuffiness-related dizziness or headache, hyposmia, sleep quality, daily life activity, work or study efficiency, mental status, and whole body fatigue, also showed less scores at month 1 and month 3 visits versus at baseline (Z value were from - 11. 313 to - 6. 802, all P <0. 01). At the same time, nasal mucosal appearances assessed by endoscopy had lower scores at month 1 (1.40±0. 62) and month 3 (0. 75 ± 0. 71) visits versus at baseline (2. 27 ± 0. 73, Z value were from - 11. 484 to - 10. 002, all P <0. 01). Additionally, adverse events were only observed in 5. 3% cases with light rhinorrhagia and nasal dryness. No other side effect was found. Conclusions A 3-months administration of intranasal mometasone can effectively and safely improve NAR patients' clinical symptom and nasal mucosal appearances.
